Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Tilrekimig in Severe chronic obstructive pulmonary disease: NCT07363694 Clinical Landscape Report 2026
16 October 2026
NCT07363694 clinical landscape for Severe chronic obstructive pulmonary disease: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
225Ac-LNC1011 in Metastatic castration-resistant prostate cancer: NCT07363486 Clinical Landscape Report 2026
16 October 2026
NCT07363486 clinical landscape for Metastatic castration-resistant prostate cancer: endpoints, sponsor, phase, geography, readouts, asset context and develop…
9 min read
68Ga-G23 in Adenocarcinoma of prostate: NCT07363382 Clinical Landscape Report 2026
16 October 2026
NCT07363382 clinical landscape for Adenocarcinoma of prostate: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tislelizumab in Hepatocellular Carcinoma: NCT07363512 Clinical Landscape Report 2026
16 October 2026
NCT07363512 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cafelkibart in stomach adenocarcinoma: NCT07362186 Clinical Landscape Report 2026
16 October 2026
NCT07362186 clinical landscape for stomach adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Albumin-Bound Paclitaxel in Advanced gastric carcinoma: NCT07361991 Clinical Landscape Report 2026
16 October 2026
NCT07361991 clinical landscape for Advanced gastric carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tegafur/Gimeracil/Oteracil Potassium in Stomach Cancer: NCT07366528 Clinical Landscape Report 2026
16 October 2026
NCT07366528 clinical landscape for Stomach Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fianlimab/Cemiplimab in Hepatocellular Carcinoma: NCT07365839 Clinical Landscape Report 2026
16 October 2026
NCT07365839 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Elfetabart drozuntecan in Metastatic castration-resistant prostate cancer: NCT07365995 Clinical Landscape Report 2026
16 October 2026
NCT07365995 clinical landscape for Metastatic castration-resistant prostate cancer: endpoints, sponsor, phase, geography, readouts, asset context and develop…
9 min read
Terbinafine Hydrochloride in Recurrent Prostate Carcinoma: NCT07365423 Clinical Landscape Report 2026
16 October 2026
NCT07365423 clinical landscape for Recurrent Prostate Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Apatinib Mesylate in Advanced gastric carcinoma: NCT07371871 Clinical Landscape Report 2026
16 October 2026
NCT07371871 clinical landscape for Advanced gastric carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Etoricoxib in Parkinson Disease: NCT07370532 Clinical Landscape Report 2026
16 October 2026
NCT07370532 clinical landscape for Parkinson Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.